Avantax Advisory Services’s Ginkgo Bioworks DNA Stock Holding History

Avantax Advisory Services’s Portfolio DNA Stock Details DNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-250	Closed	-$13.3K	–	1524
2023 Q1	$13.3K	Hold	250	–	–	﹤0.01%	1472
2022 Q4	$16.9K	Hold	250	–	–	﹤0.01%	1404
2022 Q3	$31K	Buy	+250	New	+$29.8K	﹤0.01%	1308

Other funds holding DNA

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACG

Anchorage Capital Group New York $450M AUM 41.75% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

General Atlantic New York $2.91B AUM 24.21% 1-Year Est. Return

Avantax Advisory Services's DNA Position: Q2 2023 in Review

Avantax Advisory Services sold out of Ginkgo Bioworks (DNA) in Q2 2023, closing a stake of 250 shares — an estimated $13.3K sold.

Avantax Advisory Services first reported a position in DNA in Q3 2022 and held it in 3 quarters. The position peaked at $31K in Q3 2022. 315 funds tracked by Wall St. Rank hold DNA as of Q2 2023.

Avantax Advisory Services reported no remaining Ginkgo Bioworks position as of Q2 2023 after selling out during the quarter.
Avantax Advisory Services sold 250 Ginkgo Bioworks shares in Q2 2023, an estimated $13.3K.
Avantax Advisory Services first reported a position in Ginkgo Bioworks in Q3 2022 and held it in 3 quarters.
Avantax Advisory Services's Ginkgo Bioworks position peaked at $31K in Q3 2022.
315 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q2 2023.

Based on Avantax Advisory Services's 13F filing for Q2 2023, filed 11 Aug 2023.